Riad Sherif - 06 Nov 2026 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
4
Accepted by SEC
10 Nov 2026, 16:10:33 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Todd Anderman, Attorney-in-Fact for Riad Sherif
Filing notes and source

Key filing fact

Riad Sherif filed Form 4 for OCULAR THERAPEUTIX, INC (OCUL) on 10 Nov 2026.

Key facts

  • This page summarizes Riad Sherif's Form 4 filing for OCULAR THERAPEUTIX, INC (OCUL).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 10 Nov 2026, 16:10.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002048639 Primary reporting owner

Sherif Riad

Relationship
Director
Address
C/O OCULAR THERAPEUTIX, INC., 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD
Signature
/s/ Todd Anderman, Attorney-in-Fact for Riad Sherif
Signature date
10 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCUL transaction

Common Stock

Award

Transaction value
Shares
+28,000
Change %
Price
$0.000000*
Shares after
28,000
Date
06 Nov 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCUL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+88,000
Change %
Price
$0.000000*
Shares after
88,000
Date
06 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
88,000
Exercise price
$6.60
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On November 6, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest over three years, vesting 1/3 on each yearly anniversary of the date of grant.

Footnote F2

Subject to the reporting person's continued service on the Company's board of directors, the options will vest over three years, vesting 1/3 on each yearly anniversary of the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .